Protein C News and Research

RSS

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

New technique effective in jumpstarting defective immune systems against many diseases

In a study published in Nature Medicine, Loyola researchers report on a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer.

26 Feb 2012

Skin cancer drug may prolong survival in advanced cases: Study

Researchers say 132 patients in the U.S. and Australia who were given the drug vemurafenib gained several extra months of life. The study published in the New England Journal of Medicine found that those on the drug lived an average of 16 months, compared with nine months on conventional treatment.

26 Feb 2012

Bird flu may be more common and less deadly: Study finds

The H5N1 influenza virus commonly called “bird flu” or “avian flu” could be more prevalent and less deadly than health officials had thought, according to a new study published online (Feb. 23) by the journal Science.

26 Feb 2012

Helmholtz Association grant for research on diseases caused by protein misfolding

Professor Erich Wanker of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and of the Excellence Cluster Neurocure is to receive EUR 675 000 in funding from the Helmholtz Association over the next two years. The grant shall be used to accelerate the search for active agents to treat diseases that are caused by protein misfolding. These include Alzheimer's and Parkinson's.

24 Feb 2012

UCSF: 1-2 punch blocks tumor growth, invasion and metastasis

Simultaneous targeting of two different molecules in cancer is an effective way to shrink tumors, block invasion, and stop metastasis, scientists at the University of California, San Francisco (UCSF) have found-work that may improve the effectiveness of combination treatments that include drugs like Avastin.

24 Feb 2012

New drug for Huntington's disease might operate via previously unknown mechanisms of action

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease - pridopidine or dopamine stabiliser ACR16 - might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival.

24 Feb 2012

Evolutionary forces encourage diversity in the active surfaces of venomous toxins

For snakes, spiders, and other venomous creatures, the "business end," or active part, of a toxin is the area on the surface of a protein that is most likely to undergo rapid evolution in response to environmental constraints, say researchers from Ben Gurion University in Israel.

24 Feb 2012

MRI on the nanoscale closer to realty

Magnetic resonance imaging (MRI) on the nanoscale and the ever-elusive quantum computer are among the advancements edging closer toward the realm of possibility, and a new study co-authored by a UC Santa Barbara researcher may give both an extra nudge. The findings appear today in Science Express, an online version of the journal Science.

24 Feb 2012

New Huntington's drug might operate via previously unknown mechanisms of action

24 Feb 2012

UBC develops algorithm to predict how and when proteins misfold

Several neurodegenerative diseases - including Alzheimer's and ALS (Lou Gehrig's disease) - are caused when the body's own proteins fold incorrectly, recruit and convert healthy proteins to the misfolded form, and aggregate in large clumps that gum up the works of the nervous system. "For Star Trek fans, this is like the Borg, a fictional race of cyborgs that abduct and assimilate humans and other species," says Steven Plotkin, a biophysicist at the University of British Columbia in Vancouver who studies the process of protein misfolding.

24 Feb 2012

Unfolded end of Colicin N protein can kill antibiotic-resistant microbes

When bacteria wage a turf war, some of the combatants have an extra weapon. Certain strains of the bacteria E. coli produce proteins that kill competing E. coli and other like microbes, and researchers from Newcastle University in England have recently discovered something surprising about one of these lethal proteins: even after the toxic folded portion of the protein is removed, the unfolded end is still deadly.

24 Feb 2012

UA researchers identify the likely culprit of epilepsy

Only 10 years ago, deciphering the genetic information from one individual in a matter of weeks to find a certain disease-causing genetic mutation would have been written off as science fiction. It was the time of the Human Genome Project, and it had taken armies of sequencing robots working around the clock for almost a decade to unravel the complete sequence of the human genetic code - referred to as the genome - by churning out the DNA alphabet letter by letter.

24 Feb 2012

Scientists decode two new blood types

You probably know your blood type: A, B, AB or O. You may even know if you're Rhesus positive or negative. But how about the Langereis blood type? Or the Junior blood type? Positive or negative? Most people have never even heard of these.

24 Feb 2012

Scientists identify promising strategy for HIV vaccine design

HIV has eluded vaccine-makers for thirty years, in part due to the virus' extreme ability to mutate. Physical scientists and clinical virologists from the Massachusetts Institute of Technology (MIT) and the Ragon Institute in Cambridge, Mass., have identified a promising strategy for vaccine design using a mathematical technique that has also been used in problems related to quantum physics, as well as in analyses of stock market price fluctuations and studies of enzyme sequences.

24 Feb 2012

Circadian rhythm can influence a heart attack

Researchers have found that a biological clock can influence a heart attack. The risk of “sudden cardiac death” peaks in the morning and rises again in the evening as shown in lab animals.

23 Feb 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

New CETP blockers continue to show promise as viable heart drugs

Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body.

23 Feb 2012

Scientists design compounds that act against myotonic dystrophy type 1 RNA

While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed a series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy.

23 Feb 2012

New kind of on-off switch for cortisol release in the brain discovered

After we sense a threat, our brain center responsible for responding goes into gear, setting off a chain of biochemical reactions leading to the release of cortisol from the adrenal glands.

23 Feb 2012